629.79
0.23%
1.47
Argen X Se Adr stock is traded at $629.79, with a volume of 28,116.
It is up +0.23% in the last 24 hours and up +3.94% over the past month.
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$628.32
Open:
$626.72
24h Volume:
28,116
Relative Volume:
0.11
Market Cap:
$37.48B
Revenue:
$1.86B
Net Income/Loss:
$-40.29M
P/E Ratio:
-151.39
EPS:
-4.16
Net Cash Flow:
$-1.28B
1W Performance:
-1.34%
1M Performance:
+3.94%
6M Performance:
+42.94%
1Y Performance:
+68.89%
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
629.39 | 37.48B | 1.86B | -40.29M | -1.28B | -0.85 |
VRTX
Vertex Pharmaceuticals Inc
|
407.57 | 105.01B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.17B | 13.85B | 4.65B | 3.32B | 40.41 |
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 30.94B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
114.13 | 27.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
Oct-10-24 | Resumed | Raymond James | Strong Buy |
Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Jul-31-23 | Initiated | Scotiabank | Sector Perform |
Jul-24-23 | Downgrade | UBS | Buy → Neutral |
Jul-17-23 | Resumed | Evercore ISI | Outperform |
Jun-15-23 | Initiated | Societe Generale | Sell |
May-31-23 | Initiated | UBS | Buy |
Apr-25-23 | Initiated | Citigroup | Buy |
Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
Dec-07-22 | Initiated | William Blair | Outperform |
Oct-12-22 | Initiated | Oppenheimer | Perform |
Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jun-28-22 | Resumed | Stifel | Buy |
May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Oct-07-21 | Initiated | Jefferies | Buy |
Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jul-23-21 | Initiated | Deutsche Bank | Hold |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jun-18-21 | Initiated | UBS | Buy |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Apr-23-21 | Initiated | Redburn | Neutral |
Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
Feb-10-20 | Initiated | BofA/Merrill | Buy |
Nov-05-19 | Initiated | Credit Suisse | Neutral |
Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Oct-22-19 | Initiated | JP Morgan | Overweight |
Sep-27-19 | Initiated | Wells Fargo | Market Perform |
Sep-16-19 | Resumed | Cowen | Outperform |
Jun-28-19 | Initiated | Robert W. Baird | Outperform |
Jan-18-19 | Resumed | SunTrust | Buy |
Jan-04-19 | Initiated | Morgan Stanley | Overweight |
Dec-17-18 | Initiated | Goldman | Buy |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Jun-29-18 | Initiated | Nomura | Buy |
Apr-09-18 | Initiated | SunTrust | Buy |
Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - Yahoo Finance
Idiopathic Inflammatory Myositis Industry Assessment, 2020-2034: Breakthrough Therapies (Dazukibart and Efgartigimod) Propel Market Expansion Across the 7MM - GlobeNewswire Inc.
Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar
Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com
Argenx stock soars to all-time high of $620.29 - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India
argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com
argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India
William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India
Raymond James maintains outperform on argenx, cites strong sales - Investing.com India
argenx stock climbs as Truist highlights industry-leading I&I pipeline growth - Investing.com India
Stifel sees upside in argenx stock with robust pipeline and solid 3Q results - Investing.com
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP - Investing.com Nigeria
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $589.6 amid robust growth - Investing.com
argenx ADR earnings beat by $1.24, revenue topped estimates - Investing.com
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - The Bakersfield Californian
argenx SE's SWOT analysis: biotech firm's stock poised for growth amid challenges - Investing.com
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):